SET Senior Executive Vice President Manpong Senanarong said that NAM will be listed and start trading on SET in the Consumer Products industry group, Personal Products & Pharmaceuticals sector.
NAM manufactures, imports and distributes medical devices and equipment for the cleaning, disinfection and sterilization of medical equipment in hospitals and healthcare centers in compliance with public health standards. NAM also produces and distributes consumable products for use with cleaning, disinfection and sterilization tools for medical equipment. The company's production processes meet international standards, which are on par with American and European quality standards. Significantly, NAM has developed proprietary patented medical innovations. NAM has key customer base of over 1,200 hospitals and public health organizations both domestically and internationally. NAM has been appointed as a distributor for multi-national companies, such as Steelco S.p.A, AAVI Technologies Ltd., Terragene LLC, Borer Chemie AG, and Sterimed. Furthermore, NAM also provides comprehensive related services such as after-sales service, medical tool and equipment sterilization service, medical waste decontamination service, and services for planning and upgrading the Central Sterile Supply Department (CSSD) in hospitals.
After IPO, NAM has a paid-up capital of THB 350 million with a par value of THB 0.50 each. It offered 181 million IPO shares, consisting of 105 million newly issued shares and 76 million existing common shares held by WAI Global Corporation Limited, to individuals at the underwriters' discretion, patrons, directors, executives, and employees of the company, during October 19 - 24, 2023 at THB 7.70 each, raising a total of THB 808.50 million.
Finnex Advisory Co., Ltd. and Thanachart Securities pcl are the financial advisors, and Finansa Securities Limited is the lead underwriter.
NAM Chief Executive Officer Viroj Chaiturdkiet said that NAM aims to create new products and services based on the company's innovations from inventions and R&D to expand distribution channels both locally and globally, and to diversify the customer base originally from medical organizations to other groups, such as laboratories, clinics, laboratories (human and animal), medical service providers, and households. NAM is interested in seeking opportunities to enhance growth potential in the sector of healthcare-related medical equipment. The fund raised will be used to build a new factory to raise production capacity, invest in R&D center to increase capabilities catering to medical equipment products. Moreover, NAM will invest or jointly invest in companies engaged in medical equipment businesses or having innovations that can further drive the company's business operations.
After the IPO, the company's major shareholders are the Chaiturdkiet group (the founding group) (59.14 percent) and Innobic LL Holding Co., Ltd. (a company under PTT group) (15 percent).
The company's dividend policy is to pay no less than 40 percent of net profit from the company's consolidated financial statements after corporate tax. However, such dividend payment is subject to the company's operating results, financial position, and necessity in using funds. The dividend payment will not exceed the retained earnings shown in the company's separate financial statements, and will be in accordance with relevant laws.
Investors and interested parties please see details from the company's prospectus at the Securities and Exchange Commission's website at www.sec.or.th; and for general information, please visit www.namwiwat.com as well as www.set.or.th.
Source: SET Corporate Communications